Adept adds two support staff

For expanding range of data acquisition products

Adept Scientific, based in Letchworth, Hertfordshire, UK, has taken on two new members of staff to support its expanding range of data acquisition products (DAQ).

Henrique da Silva will concentrate on DAQ sales. He has an MSc in Electronics & Computer Engineering.

Elizabeth Northrop (Lilly) will focus on technical support. She has an MEng in Systems Engineering.

With offices in the UK, Germany and throughout the Nordic region, Adept Scientific is a supplier of software and hardware products for research, scientific, engineering and technical applications on desktop computers.

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Research & Development

SPARK THE MIDLANDS backs Aston University anti-cancer bone paste collaboration

A collaboration between Aston University and Royal Orthopaedic Hospital NHS Foundation Trust has secured support from SPARK THE MIDLANDS to advance a minimally invasive gallium-doped injectable paste for treating primary and metastatic bone cancer
Subscribe now